Mitchell H. Gold, M.D. President and CEO. 2 nd Annual African American Prostate Cancer Disparity Summit September 22, 2006
|
|
- Lucy Watts
- 5 years ago
- Views:
Transcription
1 Mitchell H. Gold, M.D. President and CEO 2 nd Annual African American Prostate Cancer Disparity Summit September 22,
2 Dendreon Corporation: A Biotechnology Company on the Verge of Changing the Way Advanced Prostate Cancer is Treated Headquarters: Seattle, Washington Commercial Manufacturing: Hanover, New Jersey Founded: 1992 in Mountain View, CA No. Employees: ~220 Public Company: Nasdaq: DNDN Product Focus: Oncology 2
3 The Prostate Cancer Epidemic: Treatment Continuum A Need for Better Treatments Early Stage 511,600 1 Patients with Active Disease in 2006 Advanced Stage Primary Therapy Androgen Dependent Androgen Deprivation Androgen Independent Asymptomatic Symptomatic Radical Prostatectomy Brachytherapy Radiation Therapy Cryotherapy Watchful Waiting Lupron Zoladex Casodex Eulexin Ketoconazole Taxotere Palliative Interventions Bisphosphonates Taxotere Novantrone Emcyt 1 The Mattson Jack Group, CancerMETRIC SM database Dendreon Quantitative Primary Research, March/December ,500 1,2 Hormone Refractory Patients 96,600 1,2 Metastatic HRPC Patients 3
4 The Statistics in African American Men 30,770 new cases diagnosed each year Second leading cause of cancer related deaths African American men are diagnosed at later stages and have a 2.5 times higher mortality rate Points to need for better education and early detection Desperately need better therapies for Advanced Prostate Cancer than are currently available 4
5 Metastatic Prostate Cancer Competitive Profile Docetaxel Administration Patient Population Efficacy Safety: Grade 3/4 Event Rate Q 3 Weeks x 10 via infusion Metastatic HRPC 2.4 Month MST Advantage HR= 1.32 P=.009 Hair Loss 65% Fatigue 53% Nausea/Vomiting 42% Diarrhea 32% Neutropenia 32% Nail Changes 30% Neuropathy 30% Stomatitis 20% Peripheral Edema 19% Change in Taste 18% Anorexia 17% Dyspnea 15% Source: Taxotere label 5
6 Patients Dissatisfied With Current Treatment 100% 80% 60% 40% 52% Advanced Prostate Cancer Patients 65% 20% 0% Would Consider Chemotherapy Impact on QOL Outweighs Benefit Men with late-stage disease need more options. These men and their families shouldn t have to compromise their quality of lives. We need better treatments that fight this disease, address the most painful symptoms, and lessen the side effects of treatment. -Thomas Kirk, president and CEO of Us Too International Source: USTOO Survey Press Release, September 8, 2005; 2006 Prostate Cancer Symposia Poster #222 6
7 Androgen-Independent (Hormone-Refractory) Prostate Cancer Metastatic, androgen-independent (HRPC) prostate cancer is a deadly disease Modest survival advantage seen with docetaxel-based regimens in HRPC patients Majority of patients elect not to go on chemotherapy mostly due to impact on QOL Novel treatments and approaches with acceptable toxicity and safety profiles are needed 7
8 Sipuleucel-T: Active Cellular Immunotherapy for Advanced Prostate Cancer
9 The Prostate Cancer Treatment Continuum Sipuleucel-T Potentially Addresses Large Unmet Need Early Stage Primary Therapy Androgen Dependent Androgen Deprivation Androgen Independent Asymptomatic Advanced Stage Symptomatic Sipuleucel-T Radical Prostatectomy Brachytherapy Radiation Therapy Cryotherapy Watchful Waiting Lupron Zoladex Casodex Eulexin Ketoconazole Proposed Label: PROVENGE (sipuleucel-t) is indicated for the treatment of asymptomatic men with metastatic, androgen independent prostatic adenocarcinomas Taxotere Palliative Interventions Bisphosphonates Taxotere Novantrone Emcyt 9
10 What is Sipuleucel-T? Sipuleucel-T is an investigational Active Cellular Immunotherapy (ACI) ACIs are a new class of drug, often referred to as cancer vaccines ACIs are very different from traditional vaccines Traditional Vaccines: PREVENT disease by exposing the immune system to weakened virus or portion of a virus Cancer Vaccine/ ACIs: TREAT disease by using the body s immune system to fight the cancer Immunotherapies are designed to be specific, affecting only cancer cells. 10
11 Why Doesn t the Immune System Currently Fight Cancer? Cancer Can Avoid Detection by the Immune System Cancer cells are made up of the body s own tissues Immune system is not trained to attack them Tumors also produce substances that tell the immune system to stand down ACIs help address this problem by allowing the body to see cancer and attack it 11
12 Antigen Delivery Cassette : The Key to Generating a Robust Immune Response Targets well known antigen Prostatic Acid Phosphatase Manufacture as recombinant proteins Shown to produce a robust, reproducible and well characterized immune response in clinical studies GM-CSF Prostatic Acid Phosphatase (PAP) 12
13 Marshalling the Body s Own Resources to Fight Cancer Recombinant PAP antigen combines with resting antigen presenting cell (APC) APC takes up the antigen Antigen is processed and presented on surface of the APC Fully activated, the APC is now sipuleucel-t INFUSE PATIENT Active T-cell Inactive T-cell T-cells proliferate and attack cancer cells Sipuleucel-T activates T-cells in the body The precise mechanism of sipuleucel-t in prostate cancer has not been established. 13
14 Dendreon s Active Immunotherapy: Potential Advantages Well tolerated compared to chemotherapeutic agents Immunotherapies are designed to be specific, affecting only cancer cells Potential to be used both prior to and in combination with other agents Immune response has potential to be durable Complete course of therapy completed in one month Allows patient to resume normal quality of life 14
15 Sipuleucel-T Phase 3 Study (D9901) Basis of Biologics License Application to FDA First randomized, double blind, placebo-controlled trial of a cancer immunotherapy to show survival benefit 127 asymptomatic metastatic, AIPC patients at 19 U.S. centers Primary endpoint: Median time to objective disease progression (p-value = 0.052; HR = 1.45) Study protocol required survival follow up to 3 years after randomization 100% of patients assessed for survival Full results published in Journal of Clinical Oncology (JCO) 15
16 PROVENGE: Metastatic, Hormone Refractory Prostate Cancer D9901 Phase 3 Study Key Findings Results showed that men who received PROVENGE: Median survival time 4.5 months longer than men assigned to receive placebo 41% overall reduction in the risk of death 34% of patients were alive 36 months after treatment compared to 11% of patients randomized to receive placebo PROVENGE appears to be safe and well tolerated in 600+ patients treated in 10 clinical trials 16
17 Sipuleucel-T is Well Tolerated Event [n(%)] PROVENGE (n=82) Placebo (n=45) Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4 p-value Rigors (chills) 45 (54.9) 4 (4.9) 4 (8.9) 0 (0.0) <0.001 Pyrexia (fever) 22 (26.8) 2 (2.4) 1 (2.2) 0 (0.0) Tremor 8 (9.8) 0 (0.0) 0 (0.0) 0 (0.0) Feeling Cold 7 (8.5) 0 (0.0) 0 (0.0) 0 (0.0) Phase 3 Trial D
18 Summary of Sipuleucel-T Studies in Prostate Cancer Early Stage Androgen Dependent Study D9905 P-16 P-11 Advanced Stage Androgen Independent D9901 D9902A D9902B Phase Phase 2 Phase 2 Phase 3 Phase 3 Phase 3 Phase 3 No. of Subjects ~ ~ 500 Results Sipuleucel-T may lead to improved PSADT Sipuleucel-T plus Avastin increased PSADT 2H 2006 At 36 months, showed 4.5 month median survival benefit for men who received Sipuleucel-T At 36 months, showed 3.3 month median survival benefit for men who received Sipuleucel-T Enrolling Complete 18
19 Anticipated Regulatory Timeline Potential Advisory Committee Potential Launch Plan to Complete Submission to FDA Prior to Year End 19
20 Commercial Manufacturing Capacity in New Jersey New Jersey manufacturing facility to support clinical and future anticipated commercial capacity for Sipuleucel-T 20
21 Case Study 83 years old Diagnosis of metastatic HRPC in 2001 Significant loss of energy Gained energy after participation in clinical trial 5 years from receiving treatment Eduardo -- Prostate Cancer Survivor and Sipuleucel-T Study D9901 Patient 21
22 Survival is the ultimate goal in cancer treatment Improving survival for people with cancer is a goal worth fighting for. 22
23 23
Dendritic Cell Based Cancer Vaccine Development
Dendritic Cell Based Cancer Vaccine Development November 10, 2005 CVCWG Meeting Rob Hershberg, MD, PhD Chief Medical Officer 1 Meeting the challenges of developing cancer vaccines-- APC8015 (Provenge TM
More informationImmunotherapy Therapy for Prostate Cancer
2006 Prostate Health Education Network African American Prostate Cancer Disparity Summit Immunotherapy Therapy for Prostate Cancer Glen W. McWilliams, MD Chief of Urology James J. Peters VAMC Assistant
More informationDavid L. Urdal, Ph.D. Chief Scientific Officer The Development of Sipuleucel-T (Provenge ) for Active Cellular Immunotherapy for Prostate Cancer
David L. Urdal, Ph.D. Chief Scientific Officer The Development of Sipuleucel-T (Provenge ) for Active Cellular Immunotherapy for Prostate Cancer isbtc 22 nd Annual Meeting, Boston November 4, 2007 1 Forward
More informationPolicy. not covered Sipuleucel-T. Considerations Sipuleucel-T. Description Sipuleucel-T. be medically. Sipuleucel-T. covered Q2043.
Cellular Immunotherapy forr Prostate Cancer Policy Number: 8.01.53 Origination: 11/2010 Last Review: 11/2014 Next Review: 11/2015 Policy BCBSKC will provide coverage for cellular immunotherapy for prostate
More informationSummary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, Nasdaq: DNDN
Summary of Phase 3 IMPACT Trial Results Presented at AUA Meeting Webcast Conference Call April 28, 2009 Nasdaq: DNDN PROVENGE sipuleucel-t is an autologous active cellular immunotherapy that activates
More informationDavid L. Urdal, Ph.D. Chief Scientific Officer Sipuleucel-T for the Active Cellular Immunotherapy of Prostate Cancer
David L. Urdal, Ph.D. Chief Scientific Officer Sipuleucel-T for the Active Cellular Immunotherapy of Prostate Cancer Hot Topic Symposium; isbtc Annual Meeting October 31, 2009 1 Presenter Disclosure Information
More informationCorporate Medical Policy Cellular Immunotherapy for Prostate Cancer
Corporate Medical Policy Cellular Immunotherapy for Prostate Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: cellular_immunotherapy_for_prostate_cancers 6/2010 8/2017 8/2018
More informationGroup Sequential Design: Uses and Abuses
Group Sequential Design: Uses and Abuses Susan Halabi Department of Biostatistics and Bioinformatics, Duke University October 23, 2015 susan.halabi@duke.edu What Does Interim Data Say? 2 Group Sequential
More informationsipuleucel-t (Provenge )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationName of Policy: Cellular Immunotherapy for Prostate Cancer
Name of Policy: Cellular Immunotherapy for Prostate Cancer Policy #: 432 Latest Review Date: July 2014 Category: Medical Policy Grade: A Background/Definitions: As a general rule, benefits are payable
More informationLearn how to JUMPSTART YOUR IMMUNE SYSTEM
Learn how to JUMPSTART YOUR IMMUNE SYSTEM to attack YoUr advanced PROSTATE CANCER Starting your treatment with For more information, visit www.provenge.com Please see inside front cover and page 6 for
More informationAfrican American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study
African American Men and Prostate Cancer Management Option for Clinical PROSPECT Trial Participation in an Immunotherapy Study Jennifer Harris, PharmD Medical Science Liaison Bavarian Nordic, Inc. Prostate
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationEvolution of Chemotherapy for. Cancer
Evolution of Chemotherapy for Hormone Refractory Prostate t Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology Princess Margaret Hospital and University of Toronto In 1985, two
More informationLecture 17: Vaccines (Therapeutic and Prophylactic Types)
Lecture 17: Vaccines (Therapeutic and Prophylactic Types) Therapeutic vaccines Bacillus Calmette Guerin (BCG; TheraCys) Very old agent initially developed as vaccine for MTB. Uses: Superficial bladder
More informationProstate Cancer Vaccine - Provenge AHM
Prostate Cancer Vaccine - Provenge AHM Clinical Indications Sipuleucel-T (Provenge) is considered medically necessary for the treatment of adults with metastatic castrate-resistant prostate cancer who
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationThe Role of Immunotherapy in Prostate Cancer: What s Trending?
The Role of Immunotherapy in Prostate Cancer: What s Trending? Douglas G. McNeel, MD, PhD University of Wisconsin Carbone Cancer Center Madison, Wisconsin Prostate cancer rationale for immune therapies
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationJUMPSTART YOUR IMMUNE SYSTEM TO ATTACK YOUR ADVANCED PROSTATE CANCER
JUMPSTART YOUR IMMUNE SYSTEM TO ATTACK YOUR ADVANCED PROSTATE CANCER Talking to your doctor about For more information visit www.provenge.com Please see inside front cover and page 7 for Important Safety
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationRecent Progress in Management of Advanced Prostate Cancer
Review Article [1] April 15, 2005 By Philip W. Kantoff, MD [2] Androgen-deprivation therapy, usually with combined androgen blockade, is standard initial treatment for advanced prostate cancer. With failure
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationThe Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD
Februray, 2013 The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD Why/How my cancer is back after surgery and/or radiation? Undetected micro-metastatic disease (spreading) before local
More informationCabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel
Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a
More informationPatient: John Doe July 1, CancerOpinions MD: Luke Nordquist, M.D., F.A.C.P Zip Code: 68111
Cancer Consultation 11404 West Dodge Rd, Ste 650 Omaha, NE 68154 (402) 963-4112 (888)WEB-OPIN (932-6746) Patient: John Doe July 1, 2010 Referral MD: John Smith, MD MRN #
More informationIn autopsy, 70% of men >80yr have occult prostate ca
Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationManagement Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
Clinical Medicine Insights: Oncology Consise Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management Options in Advanced Prostate Cancer: What is
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationImmunotherapy of Prostate Cancer
Immunotherapy of Prostate Cancer Robert E. Reiter MD MBA Bing Professor of Urologic Oncology Geffen School of Medicine at UCLA Costimulatory expression required for T cell activation Therapeutic Vaccines
More informationPrevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and
More informationSAMPLE ONLY. Your Health Matters. Advanced Prostate Cancer and its Treatment A Patient Guide. Please order from Documents and Media: 415/
Your Health Matters Advanced Prostate Cancer and its Treatment A Patient Guide UCSF Genitourinary Medical Oncology Program Charles Ryan, MD, UCSF Patient Advocates Please order from Documents and Media:
More informationCLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE
FOR IMMEDIATE RELEASE CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE Results of Studies of BEXXAR TM Therapy Show Promise
More informationUpdated Results of the IMPACT. Metastatic, Castration-Resistant Prostate Cancer (CRPC)
Updated Results of the IMPACT Trial of Sipuleucel-T Tfor Metastatic, Castration-Resistant Prostate Cancer (CRPC) Philip Kantoff, MD Dana-Farber a abe Cancer Institute ue Professor of Medicine Harvard Medical
More informationSession VI A: Prostate Cancer Multidisciplinary Approach: a key to success
EORTC-GU Group Session VI A: Prostate Cancer Multidisciplinary Approach: a key to success Joaquim Bellmunt Geriatric Oncology: Cancer in Senior Adults. Madrid Melia Castilla, 8-10 November 2007. Multidisciplinary
More informationModern Screening and Treatment of Advanced Prostate Cancer John Tuckey
Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey Commonest male cancer - 2939 per year Third male cancer death 670 per year More die with it than of it but More people die of prostate
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationA Forward Look at Options for. In Prostate Cancer
A Forward Look at Options for Prostate Cancer Charles J Ryan, MD Associate Professor of Medicine Helen Diller Family Comprehensive Cancer Center University of California, San Francisco UC 1 SF UC SF Castration
More informationPhase II Clinical Trial of GM-CSF Treatment in Patients with Hormone-Refractory or Hormone-Naïve Adenocarcinoma of the Prostate
ORIGINAL RESEARCH Phase II Clinical Trial of GM-CSF Treatment in Patients with Hormone-Refractory or Hormone-Naïve Adenocarcinoma of the Prostate Robert J. Amato and Joan Hernandez-McClain Genitourinary
More informationCancer agents - Problem set #3
Cancer agents - Problem set #3 1. Define the term angiogenesis (use complete sentences). In your answer explain whether solid or liquid tumors should be more sensitive to altering angiogenesis. (Two short
More informationVaccine Therapy for Cancer
Vaccine Therapy for Cancer Lawrence N Shulman, MD Chief Medical Officer Senior Vice President for Medical Affairs Chief, Division of General Oncology Dana-Farber Cancer Institute Disclosures for Lawrence
More informationreviews LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate therapy
reviews therapy LHRH Agonists in the Treatment of Advanced Carcinoma of the Prostate Martin I. Resnick, MD, Lester Persky Professor and Chief, Department of Urology, Case Western Reserve University School
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationLUNCH AND LEARN. April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology
LUNCH AND LEARN April 17, 2018 David R. Wilkinson M.D. Gulfshore Urology Medical Therapy for Prostate Cancer Androgen (testosterone) is required for the growth of both normal prostate and prostate cancers
More informationWhat You Need to Know About Lung Cancer Immunotherapy
What You Need to Know About Lung Cancer Immunotherapy Lung.org/immunotherapy What is immunotherapy? Immunotherapy for cancer, sometimes called immune-oncology, is a type of medicine that treats cancer
More informationPhilip Kantoff, MD Dana-Farber Cancer Institute
CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests
More informationCancer Vaccines A novel approach to treat ovarian cancer ANZGOG (Australia and New Zealand Gynaecological Oncology Group) Meeting Feb 23-25, 2012
Cancer Vaccines A novel approach to treat ovarian cancer ANZGOG (Australia and New Zealand Gynaecological Oncology Group) Meeting Feb 23-25, 2012 Neil Frazer Chief Medical Officer Prima BioMed Ltd Ovarian
More informationImmunotherapy for Genitourinary Cancers. Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI
Immunotherapy for Genitourinary Cancers Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI Disclosures Madison Vaccines Inc co-founder, IP, consultant
More informationThe Role of the Medical Oncologist in the Treatment of Prostate Cancer. Alireza saadat hematologist and oncologist
The Role of the Medical Oncologist in the Treatment of Prostate Cancer Alireza saadat hematologist and oncologist When should you see an oncologist? High risk localized disease Rising PSA after local therapy
More informationJanuary Abiraterone pre-docetaxel for patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone pre-docetaxel for asymptomatic/minimally symptomatic metastatic castration resistant prostate cancer Abiraterone pre-docetaxel for patients with asymptomatic
More informationLower Baseline PSA Predicts Greater Benefit From Sipuleucel-T
Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION APRIL 12, 2018 2018 ATOSSA GENETICS, INC. ALL RIGHTS RESERVED. NASDAQ: ATOS WWW.ATOSSAGENETICS.COM 1 Forward-Looking Statements Some of the information presented herein may contain
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationMedical Treatments for Prostate Cancer
Medical Treatments for Prostate Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology, Princess Margaret Hospital and University of Toronto March 17, 2005 Brampton 1 A hypothetical
More informationPROSPECT: A Randomized, Double-blind, Global Phase 3 Efficacy Trial of PROSTVAC-VF in Men with Metastatic Castration-Resistant Prostate Cancer
PROSPECT: A Randomized, Double-blind, Global Phase 3 Efficacy Trial of PROSTVAC-VF in Men with Metastatic Castration-Resistant Prostate Cancer James L. Gulley M.D., Ph.D., F.A.C.P. Director, Clinical Trials
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationSYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223
SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:
More informationNew Treatment Options for Prostate Cancer
New Treatment Options for Prostate Cancer Moderator: Jeremy P. Goldberg, President, JPG Healthcare LLC Panelists: Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana- Farber Cancer
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationAugust 2012 Volume 10, Issue 8, Supplement 12
August 2012 Volume 10, Issue 8, Supplement 12 A SPECIAL MEETING REVIEW EDITION Highlights in Advanced Prostate Cancer From the 2012 American Urological Association Annual Meeting and the 2012 American
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More information(212) (347)
EMBARGOED FOR MONDAY, JUNE 21, 2010: 3:00 P.M. EST For immediate release: June 21, 2010 Media Contact: Curtis Allen (212) 733-2096 (347) 443-5252 Investors Contact: Suzanne Harnett (212) 733-8009 Pfizer
More informationIntermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer
MOLECULAR AND CLINICAL ONCOLOGY 3: 303-307, 2015 Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer HARUKI KUME, TAKETO KAWAI, MASAYOSHI NAGATA, TAKESHI AZUMA, HIDEYO
More informationThe Changing Landscape of Treatment Options For Metastatic Castrate-Resistant Prostate Cancer
The Changing Landscape of Treatment Options For Metastatic Castrate-Resistant Prostate Cancer Challenges and Solutions for Physicians and Patients Carole Alison Chr vala, PhD INTRODUCTION Prostate cancer
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Radium-223 chloride for the treatment of bone metastases in castrate resistant prostate cancer Draft scope Draft
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
pan-canadian Oncology Drug Review Final Clinical Guidance Report Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer October 22, 2013 DISCLAIMER Not a Substitute for Professional
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationOpen clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED
More informationFDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER
NEWS RELEASE Media Contact: Kimberly Ocampo (650) 467-0679 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Ajanta Horan (650) 467-1741 FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationTo treat or not to treat: When to treat! A case presentation
To treat or not to treat: When to treat! A case presentation Filip Ameye, MD,Phd Universitary Hospitals Leuven, Belgium Departement of Urology Prostate Center A case presentation Pt. 76 y. Mild LUTS (07/1999)
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationWhat s New in Advanced Disease (CRPC)?
What s New in Advanced Disease (castration resistant prostate cancer = CRC)? Matthew Rettig, MD Associate rofessor Department of Medicine Division of Hematology-Oncology Department of Urology Medical Director,
More informationC. Stephen Farmer, II MD Urology Associates
C. Stephen Farmer, II MD Urology Associates Benign Prostate Hypertrophy Benign Prostate Hypertrophy Symptoms Hesitancy Intermittency Nocturia Post-void dribbling Dysuria Urgency Frequency Hematuria Benign
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationCondition Spotlight: Treating Castrate Resistant (Advanced) Prostate Cancer Richard Augspurger, M.D., F.A.C.S.
Issue 12 Winter 2013 Condition Spotlight: Treating Castrate Resistant (Advanced) Prostate Cancer Richard Augspurger, M.D., F.A.C.S. When I first began practicing urology in the late 1970s, our treatment
More informationPhase 3 Top-Line Results Show IBRANCE in Combination with Fulvestrant Meets Progression-Free Survival (PFS) Primary Endpoint
For immediate release: April 15, 2015 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Announces PALOMA-3 Trial for IBRANCE (Palbociclib) Stopped Early Due
More informationNew Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일
New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationThe ODAC Chronicles: Part 5. Prostate cancer endpoints
For reprint orders, please contact reprints@future-drugs.com The ODAC Chronicles: Part 5. Prostate cancer endpoints When all has been said and done, more has been said than done! Expert Rev. Anticancer
More informationU.S. FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH
U.S. FOOD AND DRUG ADMINISTRATION + + + + + CENTER FOR BIOLOGICS EVALUATION AND RESEARCH + + + + + CELLULAR, TISSUE AND GENE THERAPIES ADVISORY COMMITTEE + + + + + OPEN SESSION + + + + + THURSDAY, MARCH,
More informationINTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER
INTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER Daniel George, MD Professor of Medicine and Surgery Director of Genitourinary Oncology Program Duke Cancer Institute 1 Disclosures Consultant:
More informationBACKGROUND. APC8015 (sipuleucel-t) is a cellular prostate cancer vaccine containing
67 Combination Immunotherapy With Prostatic Acid Phosphatase Pulsed Antigen-Presenting Cells (Provenge) Plus Bevacizumab in Patients With Serologic Progression of Prostate Cancer After Definitive Local
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationNEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)
NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationGU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017
GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer Dr. Simon Yu Nov 18, 2017 Faculty/Presenter Disclosure Faculty: Dr. Simon Yu Relationships with commercial interests: Grants/Research
More informationTreatment of Advanced Prostate Cancer
Treatment of Advanced Prostate Cancer Wm. Kevin Kelly, DO Associate Professor of Medicine and Surgery Yale University Yale University School of Medicine Advanced Prostate Cancer Metastatic Cancer Prostate
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More information